• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/22/25 8:05:53 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email
    false 0001737953 0001737953 2025-05-22 2025-05-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  May 22, 2025

     

     

     

    REPLIMUNE GROUP, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38596   82-2082553
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification Number)

     

    500 Unicorn Park Drive

    Suite 303

    Woburn, MA 01801

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (781) 222-9600

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading

    Symbol(s)

      Name of each exchange on which registered
    Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC
    (Nasdaq Global Select Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 2.02Results of Operations and Financial Condition.

     

    On May 22, 2025, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the fourth fiscal quarter and year ended March 31, 2025 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    Exhibit No.   Description
         
    99.1   News Release dated May 22, 2025
    104   Cover page interactive data file (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      REPLIMUNE GROUP, INC.
         
    Date: May 22, 2025 By: /s/ Sushil Patel
        Sushil Patel
        Chief Executive Officer

     

     

     

    Get the next $REPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    6/20/2025Overweight
    Cantor Fitzgerald
    8/28/2024$17.00Buy
    ROTH MKM
    4/17/2023$44.00Overweight
    Piper Sandler
    11/19/2021$52.00Overweight
    Piper Sandler
    10/15/2021$60.00Buy
    BTIG Research
    8/23/2021$55.00 → $49.00Outperform
    SVB Leerink
    8/9/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings